These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11183357)

  • 1. Risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.
    Aragón T; Fernyak S; Reiter R
    N Engl J Med; 2000 Oct; 343(17):1271-2; author reply 1272-3. PubMed ID: 11183357
    [No Abstract]   [Full Text] [Related]  

  • 2. Risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.
    O'Ryan M; Prado V
    N Engl J Med; 2000 Oct; 343(17):1271; author reply 1272-3. PubMed ID: 11183358
    [No Abstract]   [Full Text] [Related]  

  • 3. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion.
    Ake JA; Jelacic S; Ciol MA; Watkins SL; Murray KF; Christie DL; Klein EJ; Tarr PI
    Pediatrics; 2005 Jun; 115(6):e673-80. PubMed ID: 15930195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E. coli, antibiotics, and the hemolytic-uremic syndrome.
    Zimmerhackl LB
    N Engl J Med; 2000 Jun; 342(26):1990-1. PubMed ID: 10874069
    [No Abstract]   [Full Text] [Related]  

  • 5. E. coli, antibiotics and hemolytic-uremic syndrome in children.
    Farquhar D
    CMAJ; 2000 Aug; 163(4):438. PubMed ID: 10976267
    [No Abstract]   [Full Text] [Related]  

  • 6. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections.
    Wong CS; Jelacic S; Habeeb RL; Watkins SL; Tarr PI
    N Engl J Med; 2000 Jun; 342(26):1930-6. PubMed ID: 10874060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibiotic treatment of Escherichia coli O157 infection and the risk of hemolytic uremic syndrome, Minnesota.
    Smith KE; Wilker PR; Reiter PL; Hedican EB; Bender JB; Hedberg CW
    Pediatr Infect Dis J; 2012 Jan; 31(1):37-41. PubMed ID: 21892124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antimotility agents and E. coli infection.
    Tarr PI; Christie DL
    CMAJ; 1999 Apr; 160(7):984, 986. PubMed ID: 10207332
    [No Abstract]   [Full Text] [Related]  

  • 9. Escherichia coli infections and hemolytic-uremic syndrome.
    Romney M
    CMAJ; 2001 May; 164(10):1406. PubMed ID: 11387907
    [No Abstract]   [Full Text] [Related]  

  • 10. Escherichia coli O157:H7 as the predominant pathogen associated with the hemolytic uremic syndrome: a prospective study in the Pacific Northwest.
    Neill MA; Tarr PI; Clausen CR; Christie DL; Hickman RO
    Pediatrics; 1987 Jul; 80(1):37-40. PubMed ID: 3299236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Escherichia coli infections and hemolytic-uremic syndrome.
    Cimolai N
    CMAJ; 2001 May; 164(10):1405-6. PubMed ID: 11387906
    [No Abstract]   [Full Text] [Related]  

  • 12. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis.
    Safdar N; Said A; Gangnon RE; Maki DG
    JAMA; 2002 Aug; 288(8):996-1001. PubMed ID: 12190370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Child care-associated outbreak of Escherichia coli O157:H7 and hemolytic uremic syndrome.
    Raffaelli RM; Paladini M; Hanson H; Kornstein L; Agasan A; Slavinski S; Weiss D; Fennelly GJ; Flynn JT
    Pediatr Infect Dis J; 2007 Oct; 26(10):951-3. PubMed ID: 17901803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Escherichia coli O157:H7 hemorrhagic colitis.
    Tarr PI; Neill MA; Christie DL; Anderson DE
    N Engl J Med; 1988 Jun; 318(25):1697. PubMed ID: 3287166
    [No Abstract]   [Full Text] [Related]  

  • 15. Strength of the association between antibiotic use and hemolytic uremic syndrome following Escherichia coli O157:H7 infection varies with case definition.
    Tarr GAM; Oltean HN; Phipps AI; Rabinowitz P; Tarr PI
    Int J Med Microbiol; 2018 Oct; 308(7):921-926. PubMed ID: 30257808
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial and antimotility agent use in persons with shiga toxin-producing Escherichia coli O157 infection in FoodNet Sites.
    Nelson JM; Griffin PM; Jones TF; Smith KE; Scallan E
    Clin Infect Dis; 2011 May; 52(9):1130-2. PubMed ID: 21467017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A cluster of Escherichia coli O157:H7 infections with the hemolytic-uremic syndrome and death in California. A mandate for improved surveillance.
    Shefer AM; Koo D; Werner SB; Mintz ED; Baron R; Wells JG; Barrett TJ; Ginsberg M; Bryant R; Abbott S; Griffin PM
    West J Med; 1996; 165(1-2):15-9. PubMed ID: 8855679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escherichia coli O157:H7 gastroenteritis and the hemolytic uremic syndrome: an emerging infectious disease.
    Besser RE; Griffin PM; Slutsker L
    Annu Rev Med; 1999; 50():355-67. PubMed ID: 10073283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging clinical importance of non-O157 Shiga toxin-producing Escherichia coli.
    Johnson KE; Thorpe CM; Sears CL
    Clin Infect Dis; 2006 Dec; 43(12):1587-95. PubMed ID: 17109294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of hemolytic uremic syndrome from antibiotic treatment of Escherichia coli O157:H7 colitis.
    Tarr PI; Watkins SL; Neill MA
    JAMA; 2002 Dec; 288(24):3111-2; author reply 3112. PubMed ID: 12495389
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.